MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone973-509-0444
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$530,000.00
Profitability
Miscellaneous
Employees10
Next Earnings Date3/26/2019 (Estimated)
OptionableNot Optionable
MYOS (NASDAQ:MYOS) Frequently Asked Questions
What is MYOS's stock symbol?
MYOS trades on the NASDAQ under the ticker symbol "MYOS."
How were MYOS's earnings last quarter?
MYOS Co. (NASDAQ:MYOS) issued its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.06. The business earned $0.09 million during the quarter, compared to analyst estimates of $0.20 million. MYOS had a negative net margin of 1,152.17% and a negative return on equity of 117.13%. View MYOS's Earnings History.
When is MYOS's next earnings date?
Has MYOS been receiving favorable news coverage?
News stories about MYOS stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MYOS earned a news impact score of 1.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of MYOS's key competitors?
Some companies that are related to MYOS include DiaMedica Therapeutics (DMAC), Oncomed Pharmaceuticals (OMED), ProPhase Labs (PRPH), AzurRx BioPharma (AZRX), OncoSec Medical (ONCS), Moleculin Biotech (MBRX), Achaogen (AKAO), Addex Therapeutics (ADDXF), Sophiris Bio (SPHS), Adial Pharmaceuticals (ADIL), GTX (GTXI), Oncolytics Biotech (ONCY), Novan (NOVN), Heat Biologics (HTBX) and Genprex (GNPX).
What other stocks do shareholders of MYOS own?
Who are MYOS's key executives?
MYOS's management team includes the folowing people:
- Mr. Joseph Mannello, CEO & Director (Age 61)
- Mr. Ren Ren, Global Chairman (Age 57)
- Mr. Joseph DiPietro, Controller
- Mr. Magshoud Dariani, Chief Technology Officer
- Mr. Kris Ohrenick, Head of Marketing
Who are MYOS's major shareholders?
MYOS's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Pinnacle Wealth Management Advisory Group LLC (1.82%), Pinnacle Associates Ltd. (1.82%) and Virtu Financial LLC (0.45%). Company insiders that own MYOS stock include Christopher Pechock and Joseph Mannello. View Institutional Ownership Trends for MYOS.
Which institutional investors are buying MYOS stock?
MYOS stock was bought by a variety of institutional investors in the last quarter, including Pinnacle Wealth Management Advisory Group LLC, Pinnacle Associates Ltd. and Virtu Financial LLC. Company insiders that have bought MYOS stock in the last two years include Christopher Pechock and Joseph Mannello. View Insider Buying and Selling for MYOS.
How do I buy shares of MYOS?
Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MYOS's stock price today?
One share of MYOS stock can currently be purchased for approximately $1.60.
How big of a company is MYOS?
MYOS has a market capitalization of $10.66 million and generates $530,000.00 in revenue each year. The company earns $-4,050,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. MYOS employs 10 workers across the globe.
What is MYOS's official website?
How can I contact MYOS?
MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected]
MarketBeat Community Rating for MYOS (NASDAQ MYOS)
MarketBeat's community ratings are surveys of what our community members think about MYOS and other stocks. Vote "Outperform" if you believe MYOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
